QUOTE AND NEWS
Marketwire  Nov 10  Comment 
MENLO PARK, CA -- (Marketwire) -- 11/10/09 -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery and development of drugs for the treatment of severe metabolic and psychiatric disorders, today reported
TheStreet.com  Oct 13  Comment 
Corcept Therapeutics rallied Tuesday on heavy volume after announcing plans to raise about $18 million by selling stock and options to institutional investors.
Marketwire  Oct 13  Comment 
MENLO PARK, CA -- (Marketwire) -- 10/13/09 -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the development of drugs for the treatment of severe metabolic and psychiatric disorders, today announced that it has
Business Wire  Sep 9  Comment 
CORT announces a national purchase-leaseback program that allows companies to transform office furniture into cash for strategic investments. CORT, a Berkshire Hathaway company (NYSE: BRK.A and BRK.B) and the nation’s leading furniture rental
Marketwire  Aug 11  Comment 
MENLO PARK, CA -- (Marketwire) -- 08/11/09 -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the development of drugs for the treatment of severe metabolic and psychiatric disorders, today reported financial
Marketwire  May 11  Comment 
MENLO PARK, CA -- (Marketwire) -- 05/11/09 -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the development of drugs for the treatment of severe psychiatric and metabolic disorders, today reported financial
Pharma's Cutting Edge  Aug 26  Comment 
Nothing particularly revelatory in this post--just a couple quick reminders if you will. I don't follow Corcept, and I hadn't heard of Corlux until I'd read this press release. On the other hand, I have heard of (and prescribed) the active...
Suggest a News Source
Topic
Top news source/blog that we're missing
Why do you recommend this news source?
Close 
Thanks for your suggestion!
 


 
CORT AT A GLANCE
P/E -6.64 
EV/EBITDA -7.15 
ROA -116.6%AVG
ROE -138%AVG
Debt to Equity 0.255AVG
Current Ratio 4.84AVG
 
 
 
 
 
 
 
 




References

Wikinvest © 2006, 2007, 2008, 2009. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki